ArticleThe Lancet regional health. Western Pacific2026
Projections of diabetes mellitus in Japan through 2040: a bayesian age-period-cohort analysis of the national health and nutrition survey population.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate projection of the burden of diabetes mellitus (DM) requires consideration of age, period, and cohort (APC) effects underlying prevalence trends. We estimated projected trends in DM prevalence and case numbers in Japan from 2020 until 2040, by sex, using the Bayesian APC (BAPC) model. Methods: We employed Bayesian age-period-cohort modeling and prediction (BAMP), using observed populations (aged 40 years or older) and DM cases from the National Health and Nutrition Survey from 2003 to 2019, to project national-level DM prevalence and cases from 2020 to 2040 using the national-level projected population until 2040. We further compared BAPC's predictive performance with that of conventional prediction model 1 with a constant prevalence rate and conventional prediction model 2 with a monotonically changing prevalence rate, using root mean square error (RMSE) between observed and projected case numbers for model validation during 2015-2019. Findings: The prevalence (95% credible intervals) of DM in Japan was projected to increase from 16.4% (12.3%-21.6%) in 2020 to 18.1% (6.4%-40.8%) in 2040 in men by BAPC, while it was projected to decline from 9.6% (6.8%-13.3%) to 7.7% (2.3%-22.7%) in women, variations primarily suggested by age effects and cohort effects. DM cases (95% credible intervals) are expected to increase from 6,070,000 (4,530,000-7,980,000) in 2020 to 6,336,000 (2,230,000-14,290,000) in 2040 in men, while they were expected to decline from 3,995,000 (2,840,000-5,540,000) to 3,032,000 (910,000-8,910,000) in women. The BAPC demonstrated the best predictive performance with lower RMSE (men, 40.1; women, 11.5), compared to conventional model 1 (men, 51.3; women, 20.8) and conventional model 2 (men, 42.4; women, 23.1). Interpretation: This study suggests that Japan is expected to experience increases in the prevalence and number of DM cases from 2020 to 2040, particularly among men, given the APC factors. Funding: This research was supported by JSPS KAKENHI Grant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.